Cargando…
Profile of farletuzumab and its potential in the treatment of solid tumors
Folate receptor (FR) α expression in normal tissues is restricted to a subpopulation of epithelial cells. In contrast, FRα is overexpressed in epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma. Therefore, FRα is considered a promising therapeutic target for EOC and non-small-cell lun...
Autores principales: | Sato, Seiya, Itamochi, Hiroaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789847/ https://www.ncbi.nlm.nih.gov/pubmed/27022278 http://dx.doi.org/10.2147/OTT.S98242 |
Ejemplares similares
-
A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors
por: Sasaki, Yasutsuna, et al.
Publicado: (2014) -
Evaluation of therapeutic efficacy of (211)At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer
por: Palm, Stig, et al.
Publicado: (2020) -
Profile of veliparib and its potential in the treatment of solid tumors
por: Wagner, Lars M
Publicado: (2015) -
Profile of panobinostat and its potential for treatment in solid tumors: an update
por: Anne, Madhurima, et al.
Publicado: (2013) -
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer
por: Farrell, Colm, et al.
Publicado: (2012)